The 4 drugs tracked here made $28.4B of Johnson & Johnson’s 2025 revenue (30%) and lose US exclusivity by 2032. Since 2023, Johnson & Johnson has closed 5 acquisitions of $1B or more, worth $21.9B in total.
Bars are each drug's 2025 sales as a share of Johnson & Johnson’s total revenue ($94.2B). Total includes MedTech. Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Mar 2024 | Ambrx BiopharmaJ&J, March 2024 | $2.0B | Oncology | Antibody-drug conjugates, led by ARX517 for prostate cancerAbout $1.8B net of cash acquired. | Pipeline only |
| Jul 2024 | Yellow Jersey TherapeuticsJ&J, July 2024 | $1.25B | Immunology | NM26, a bispecific antibody for atopic dermatitis | Pipeline only |
| Apr 2025 | Intra-Cellular TherapiesJ&J, April 2025 | $14.6B | Neuroscience | Caplyta, approved for schizophrenia and bipolar depression | Approved product |
| Dec 2025 | Halda TherapeuticsJ&J, December 2025 | $3.05B | Oncology | HLD-0915, an oral prostate cancer drug in clinical trials | Pipeline only |
| Jul 2026 | Firefly BioJ&J, July 2026 | $1.0B | Oncology | An early platform for degrader-antibody conjugates in solid tumors | Pipeline only |
| 5 deals | $21.9B | ||||
Acquisitions of whole companies worth $1B or more, announced since January 2023. Values are the headline price Johnson & Johnson announced, excluding milestone payments unless noted. Licensing deals are not included.
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Oncology | $17.2B | $6.05B |
| Neuroscience | – | $14.6B |
| Immunology | $11.2B | $1.25B |
Johnson & Johnson has the most revenue at risk in oncology, but has spent the most on acquisitions in neuroscience. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Johnson & Johnson paid, not the sales it will bring in. Only one of the 5 companies it bought was already selling an approved product at closing (Intra-Cellular Therapies); the rest brought pipeline drugs whose sales are years away and may never arrive. So this page shows the two side by side rather than claiming how much of the gap the deals fill.
Amgen's Wezlana launched in January 2025, and several more biosimilars followed during the year. Stelara sales fell 41% in 2025. Center for Biosimilars
Revenue: J&J FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Johnson & Johnson’s announcement or filing in the table above.
See all 45 drugs on the patent cliff →